期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 16, 期 10, 页码 1718-1723出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.45123
关键词
Neutralizing antibody; SARS-CoV-2; COVID-19; severe acute respiratory syndrome
资金
- Science and Technology Development Fund of Macau [FDCT/131/2016/A3, FDCT/0015/2018/A1]
- National Key R&D Program of China [2019YFA0904400]
- Multi-Year Research Grant [MYRG2019-00069-FHS]
- Start-up Research Grand [SRG2016-00082-FHS]
- intramural research program of Faculty of Health Sciences, University of Macau
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据